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Parkinson’s disease is a progressive neurodegenerative disease that causes debilitating 
motor deficits in addition to many non-motor symptoms. Tremors, stiffness, and abnormal 
gait changes are easily recognized as disabling; however, effects from anxiety are more 
insidious to disease burden which negatively affect both motor and psychological 
capabilities. Anxiolytics or antidepressants are often prescribed but can cause adverse side 
effects, prompting the need for alternative treatments. Yoga and mindfulness therapies are 
favorable alternative treatments known to reduce anxiety. This two-arm, single-blinded 
randomized controlled trial compares effects of yoga and mindfulness therapies in the 
reduction of anxiety for patients with Parkinson’s disease. Yoga is hypothesized to have 
greater statistically significant effect in reducing anxiety compared to mindfulness due to 
its combined mental and physical benefits. However, if both interventions demonstrate 
positive outcomes, both may prove to be beneficial adjunctive treatments for patients with 
















CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Overview of Parkinson’s Disease and Related Anxiety 
Parkinson’s disease (PD) is a progressive neurodegenerative disease that results in 
debilitating motor and cognitive deficits that drastically decrease quality of life and health 
status. There is a direct association between the incidence of PD with aging; as such, 
prolonged life expectancies in recent decades contribute significantly to the increase in 
diagnoses and subsequent healthcare expenditures.1 In 2020, one million US citizens 
were estimated to be living with PD; and the prevalence has been projected to increase by 
at least 60,000 patients per year.1 The annual healthcare expenditures were estimated to 
be $12,350 - $17,136 per patient in 2020.2  
Although the inciting factor triggering idiopathic Parkinson’s disease has not been 
identified, the underlying neuropathology and symptomology of Parkinson’s disease have 
been well-established. Abnormal α-synuclein accumulations in various cells including 
Lewy bodies result in the degeneration of dopaminergic neurons in the substantia nigra.3 
The resultant loss of dopamine supply for this area of the brain disrupts the coordination 
of movements which results in tremors, bradykinesia, and rigidity. 4,5 Although the 
development of motor symptoms is often gradual, actual rates of progression may differ 
among each patient. Unfortunately, PD is neither reversible nor curable. 
In addition to the more classic motor symptoms of PD, there are psychological 
symptoms that accompany the disease. The underlying pathophysiology of the 
psychological changes is also not fully understood, but most research in this area has 
implicated alterations in dopaminergic system and transporter availability, structural 
amygdala changes, and loss of noradrenaline neurons in the locus coeruleus as potential 
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etiologies.6 Other neurobiological explanations include disruptions of frontal-striatal 
circuits that regulate stress, cognition, affect, motivation, and behavior.7  
The diminished abilities to regulate new physical and emotional stressors from 
PD often result in secondary diagnoses of anxiety disorders at a later age. Anxiety 
disorders as determined by DSM-V have been diagnosed in patients with Parkinson’s 
disease and include generalized anxiety disorder (14%), social anxiety disorder (13.8%), 
anxiety not otherwise specified (NOS) (13.3%), specific phobia (13%), and panic 
disorder (6.8%).5  
1.1.2 Treatments of Parkinson-Related Anxiety 
A study conducted by Broen et al. in 2016 revealed that 31.1% of patients with 
Parkinson’s disease (PwP) had anxiety disorders or clinically relevant anxiety 
symptoms.8 Despite being a fairly prevalent symptom experienced by PwP, there are no 
formal guidelines for treatment of anxiety in this population.8,9 Several agents including 
Bromazepam, selective serotonin reuptake inhibitors (SSRI), and cognitive behavioral 
therapies (with or without pharmacotherapy) have been trialed to varying efficacies.10 
Many of these therapies also have the potential to lead to adverse drug interactions and 
debilitating side effects, sometimes resulting in higher healthcare expenditures.11  
In the search for cost-effective therapies, researchers have turned towards 
investigating psychological treatments that aim to reduce negativity in internal responses 
to emotional or physical situations that may trigger anxiety.12  
A precedent has been set for the use of alternative therapies such as mindfulness 
or yoga in progressive neurological disorders such as multiple sclerosis (MS) and 
Huntington’s disease (HD). These disorders closely resemble PD in their multisystemic 
disease course, neurodegeneration, and incurability.7 In a systematic literature review, 
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mindfulness based therapies were found to have a greater positive effect in patients with 
MS-related anxiety than antidepressants in patients with PD-related anxiety.7 Although 
mindfulness was not studied for PD-related anxiety, the authors suggested that 
mindfulness had high potential in reducing PD-related psychological distress. 
Mindfulness has been shown to effectively increase self-awareness while 
preventing habitual and negative responses to emotions or physical impairments.13 This is 
accomplished through increased attention and self-awareness of emotions, sensory 
perceptions, and thinking patterns in a non-judgmental manner.10 The response to difficult 
situations then becomes slowed and methodical—leading to less anxiety and an enhanced 
repertoire of coping skills over time.14 The medial cortex, amygdala, lateral frontal 
regions, hippocampus, and basal ganglia have all been studied to be affected by 
mindfulness.15 Specifically, it has been demonstrated that mindfulness down-modulates 
outputs from the amygdala, which has been associated with reductions in anxiety and 
fear-related behaviors.16,17 While there is ongoing investigation on the effect of 
mindfulness on other cortical structures, impact studies have demonstrated that 
mindfulness has shown positive effects on quality of life based on both mental health and 
well-being questionnaires.16  
With yoga, the psychological benefits have been associated with relaxation of the 
physical body. Research findings indicate that yoga decreases emotional stress and 
reduces the autonomic sympathetic, fight-or-flight heightened responses.18 Yoga has also 
been shown to directly reduce the oxidative stress that results in dopaminergic 
neurodegeneration in the substantia nigra. The oxidative stress involving reactive oxygen 
and nitrogen species along with diminished antioxidant protection cause improper 
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skeletal muscle contraction and muscle fatigue.19,20 The physical practice of yoga 
exercises and poses are known to reduce oxidative stress by increasing both endogenous 
enzymatic and nonenzymatic antioxidants.20 The result contributes to a slowing of the 
loss of dopaminergic neurons, which in turn reduces the disruption to the previously 
described frontal-striatal circuits that control mood and behavior.  
Other theorized effects of yoga includes a downregulation of the hypothalamic-
pituitary-adrenal axis as a means of reducing anxiety.21 Studies in this area have shown 
that deep breathing, meditation, and active exercises in yoga correlate with reduced levels 
of cortisol and catecholamines, and increased levels of serotonin, melatonin, and GABA. 
These changes in neurotransmitter activity have all been implicated in promoting positive 
mental health benefits.22 The increase in GABA neurotransmitters in yoga is a 
mechanism of action that many anxiolytics, like benzodiazepines, attempt to mimic 
exogenously.23 Breath control in yoga has been studied and found to benefit anxiety and 
panic disorder by activating the parasympathetic nervous system via vagal stimulation 
and reducing the activity of the sympathetic nervous system.23 
To date, there have been no head-to-head studies comparing the efficacy of yoga 
and mindfulness in decreasing anxiety. It is suspected that yoga may demonstrate a more 
significant reduction in anxiety over mindfulness due to combined physical and 
neurochemical responses like increased endogenous opioids, which improve moods and 
decrease pain.23  
1.2 STATEMENT OF THE PROBLEM  
Studies have shown that high levels of anxiety lead to accelerated motor 
dysfunction, poor treatment compliance, and rejection of leisure and social activities.11 
These changes all drastically decrease quality of life.24,25 Many pharmacological agents 
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with anxiolytic properties like SSRI, buspirone, and benzodiazepines have been tried in 
Parkinson populations. But, many of these agents block dopamine or increase risk for 
falls and confusion, making them especially dangerous in patients with primary physical 
and/or cognitive impairments.11 The dopaminergic therapies that are used to alleviate 
motor symptoms in Parkinson’s are minimally efficacious toward the psychological 
symptoms that patients experience. In some instances, dopaminergic treatments may 
worsen such symptoms. Treatment of non-motor symptoms typically subjects patients to 
polypharmacy, unwanted side effects, and higher medical expenditures. Despite the 
relatively high prevalence of anxiety in patients with Parkinson’s disease, there are very 
few studies that address anxiety as primary outcomes;11 or, evaluate non-pharmacological 
options for treatments of Parkinson’s-related anxiety.24 
1.3 GOALS AND OBJECTIVES  
Patients with Parkinson’s disease would benefit from low-cost, low-risk 
nonpharmacological therapies designed to improve functional abilities across multiple 
domains (physical, cognitive, and mood/affect). Research-based outcomes indicated that 
both mindfulness therapy and yoga therapy improve psychological symptoms.26 Our 
objective is to determine which therapy has greater impact in reducing anxiety in patients 
with Parkinson’s Disease. This study will be designed and powered to examine reduction 
of anxiety as the primary outcome. The study will also utilize inventories and indexes 
tailored specifically for Parkinson’s anxiety.  
1.4 HYPOTHESIS 
Patients with Parkinson’s disease who practice yoga weekly for 8 weeks will have 
statistically significant mean differences in anxiety scores on the Parkinson Anxiety Scale 
(PAS) and Beck Anxiety Inventory (BAI) as compared to patients who practice 
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mindfulness-based therapies for the same number of sessions. We expect to see decreases 
in anxiety-related symptoms as our primary outcome. The secondary outcomes will be 
improvements in health status, motor symptoms, and changes in anxiety medication 
usage. We also hypothesize that the benefits of both therapies will be maintained at 3-
months and 6-months post-intervention. 
1.5 DEFINITIONS  
Mindfulness Therapy – conscious awareness, openness, and non-judgment of present 
moment 
 
Yoga Therapy – Specific application of yoga activities (postures, breathing, meditation) 
used to aid recovery or rehabilitation from illness, injury, or disability22 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 INTRODUCTION 
From August 2020 to May 2021, a systematic literature search was carried out on 
PubMed, Cochrane, and Scopus with different combinations of the key terms: 
“Parkinson* anxiety”, “Parkinson*” “antidepressants”, “Parkinson* AND tricyclic 
antidepressants”, “Beck anxiety Parkinson”, “Parkinson Anxiety Scale”, “CBT”, “yoga”, 
“yoga therapies”, “mindfulness”, and “mindful meditation”. The following MeSH 
phrases were also used on PubMed: “Parkinson* anxiety”, “yoga”, and “mindfulness”. 
Results were narrowed with filters for publication dates in the last decade and the 
following article types: randomized controlled trial, meta-analysis, and systematic 
literature review. On CINAHL, the following were searched: (MH "Parkinson Disease") 
AND (MH "Anxiety+") “yoga therapy” “mindfulness” and “anxiety disorders”. Several 
articles were also extracted from the reference lists of other articles. 
2.2 REVIEW OF EMPIRICAL STUDIES 
2.2.1 Overview of Pharmacological Therapies in Parkinson-Related Anxiety 
Systematic literature reviews performed by Broen et al. on Parkinson-related 
anxiety revealed that an average of 31% of patients with Parkinson’s disease met criteria 
for DSM-V anxiety disorders and another 25.7% for clinically significant anxiety 
symptoms.1 Despite the importance of anxiety and psychological disability in PD, there 
were limited numbers of well-designed controlled studies regarding prescribing practices 
in this population.2 A cross-sectional study by Pontone et al. demonstrated that among 38 
patients with Parkinson-related anxiety, only 53% were actively receiving 
pharmacological treatment.3 Of those receiving treatment, the most commonly used 
anxiolytics were selective serotonin reuptake inhibitors (SSRI), with 30.1% and 38.9% 
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prescribed in patients with and without depression, respectively.3 This was in contrast to 
benzodiazepines, which were the medication of choice for non-PD populations.3 The 
avoidance of benzodiazepines in patients with Parkinson’s (PwP) was based on the 
known side effects such as increased fall risks, cognitive impairment, and medication 
dependency.3 
Although the study by Pontone et al. provided useful documentation of the 
prescription patterns in Parkinson-related anxiety, it lacked the details of treatment 
schedules and efficacies.4 The study also did not account for the use of alternate, non-
pharmacological therapies in Parkinson-related anxiety. Additional studies are necessary 
to determine the efficacy of pharmacological treatments as well as the reasons for low 
prescription rates.  
2.2.2 The Effects of Mindfulness on Anxiety  
In recent years, the use of mindfulness-based interventions has become more 
prevalent due to its low-cost and convenience as a psychological treatment. Research 
pursuits have focused on assessing its efficacy in anxiety syndromes both as an 
independent treatment option and as an adjunct to other treatment modalities.5,6 
Boettcher and Kladnitski et al. each performed randomized controlled trials and 
separately found online mindfulness programs to be effective for primary anxiety 
disorders (social anxiety disorder, panic disorder, general anxiety disorder, and anxiety 
not-otherwise-specified). In the Boettcher et al. study, 91 patients were assigned to either 
an online mindfulness treatment group or an online discussion forum control group.7 
Participants showed decreases in symptoms of anxiety, depression, and insomnia with 
more notable reductions from pre- to post- assessment (Cohen’s d=1.58) in the 
mindfulness group as compared to the control group (d=0.49).7 The primary outcomes 
 11 
measured on the Beck Anxiety Inventory (BAI) also showed large group differences 
(d=0.99) post-treatment between the two treatment groups.7,8 Clinically, 16 participants 
(40%) of the mindfulness group achieved the criteria of improvement and recovery 
compared to 4 participants (9%) in the control group. These differences in response rate 
were deemed significant (χ2 = 11.04, p = 0.002).7 However, the anxiety scores between 
post-intervention to 6-month follow up were not determined to be significant (t = -0.95, 
p=0.347).7  
Kladnitski et al. took a similar approach and delivered mindfulness sessions 
online over a 14-week period for patients with primary DSM-V based diagnoses of 
primary anxiety and major depressive disorders.8 Within the mindfulness group, a 
reduction of 1.08 (95% CI of 0.55 to 1.60) was found between baseline and post-
treatment, and 1.14 (95% CI of 0.60 to 1.69) from baseline to 3-month follow-up.8 This 
was in contrast to the treatment-as-usual (TAU) response of 0.34 (95% CI of -0.14 to 
0.82) from baseline to post-treatment. The response from baseline to follow-up was not 
reported in the TAU group.8 The comparison of reduction in anxiety between the 
mindfulness and TAU interventions was significant at 1.00 (95% CI of 0.46 to 1.54) post-
intervention. These results were unexpectedly greater than the moderate differences 
found in other studies.8 Clinically, 73.1% of the 40 participants in the mindfulness group 
no longer met the DSM-V criteria for anxiety or depressive disorders at 3-months follow-
up; however, an attrition rate (23-35%) suggested that these improvements may not be 
sustainable.8  
The Kladnitski et al. study was sufficiently powered to detect statistically 
significant differences between interventions and treatment as usual care, but revealed 
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that the benefits of mindfulness may not necessarily be maintained beyond treatment 
completion without continued observance of mindfulness practices.8 The authors 
surmised that future trials would likely require at least 200 participants in each group to 
achieve statistical significance between mindfulness and TAU.8 Based on these findings, 
it was also suggested that mindfulness training was a viable stand-alone therapy option 
for individuals with anxiety, and that daily use of mindfulness therapy will support long-
term benefits.8 Since both Boettcher and Kladnitski et al. concluded that three months 
was an insufficient duration to conduct post-treatment follow-up, future studies should 
have longer monitoring periods in order to more accurately comment on the long term 
efficacy of mindfulness treatments.7,8  
Sundquist et al. conducted a head to head comparison study on mindfulness-based 
interventions (MBI) against cognitive behavioral therapy (CBT) and pharmacological 
treatments.6 Their qualifying inclusion criteria covered a broad range of anxiety disorders 
that included all the diagnoses similarly observed in patients with Parkinson’s (panic 
disorder, GAD, mixed anxiety and depressive disorder, other mixed anxiety disorders, 
and anxiety NOS).6 This study did not target patients with Parkinson’s disease. The MBIs 
group had drastically decreased the median scores on the anxiety subscale of the Hospital 
Anxiety and Depression Scales (HADS) from baseline to post-intervention assessment (p 
< 0.001).6 Primary outcomes of HADS also revealed that MBIs were not inferior to CBT 
or pharmacological treatment controls (97.5% one-sided CI with an upper limit 3.16).6 
Unfortunately, the study population was restricted to participants 20-64 years old,6 and as 
such, results could not be generalized to older populations or Parkinson’s patients, who 
are generally >60 years old.9   
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Dissanayaka utilized a specific mindfulness training, called Mindfulness-Based 
Stress Reduction (MBSR), which facilitates adaptation to the stress and management of 
medical illnesses.10 This study was designed specifically to determine efficacy of the 
mindfulness training for reduction of motor and neuropsychiatric deficits in PwP.10 
Dissanayaka believed that mindfulness practices would improve selective and sustained 
attention, working memory, executive functioning, and motor ability, which would prove 
especially beneficial for PwP.10 Anxiety-related symptoms were assessed using the 
Geriatric Anxiety Inventory (GAI). Outcomes demonstrated that the postintervention 
mean GAI scores were significantly reduced from baseline (Z= - 2.20, p=0.03), and that 
21% of the 14 participants experienced clinically significant reductions in their anxiety-
related symptoms.10 
Limitations to this study were that the sample size was small. Outcomes indicated 
no significant differences between the mean GAI scores from baseline to 6-months 
follow-up (Z= -1.29, p= 0.20).10 This finding, along with the findings from Kladnitski et 
al. study, suggested that the benefits of mindfulness may be nullified if consistent 
practice is not maintained post-intervention.10 As for motor symptoms, the scores from 
the Movement Disorder Society-United PD Rating Scale did not show improvements in 
follow-up and post-intervention from baseline.10  
2.2.3 The Effects of Yoga on Anxiety 
Yoga promotes both physical and psychological well-being11 through various 
techniques that include physical postures (asanas), breath regulation (pranayama), 
meditation/mindfulness, and relaxation.12 Over the past two decades, yoga has been 
revitalized in mainstream culture, but internationally it has already been accepted as a 
form of complementary medicine for both physical and mental health.13-15  
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Cramer et al. conducted a systematic meta-analysis to assess the efficacy and 
safety of yoga in patients with a wide scope of anxiety disorders.13 The research included 
adults with mean ages 30-38.5 years old, who met DSM-IV criteria for primary anxiety 
disorders or who scored moderate or higher for anxiety according to clinical anxiety 
rating scales and questionnaires.13 Primary anxiety outcomes included improvements in 
the severity of anxiety or complete remission of anxiety based on objective clinician-
rated or subjective self-rated scales.13  
The meta-analysis revealed that yoga had positive, short-term effects (12 weeks 
from randomization) on anxiety compared to no treatment based on standardized mean 
differences (SMD) = -0.43; 95% CI = -0.74 to -0.11; P=0.008.13 When compared to other 
relaxation techniques such as meditation, yoga showed an even greater reduction of 
anxiety (SMD = -0.86; 95% CI = -1.56 to -0.15; P=0.02). The results of this meta-
analysis were not without limitations. Beyond the 12 weeks of study, there were no 
changes in the remission of anxiety between intervention and control groups.13 Cramer et 
al. also found that a statistical significance was not achieved in subjects with DSM-IV 
diagnosed anxiety disorders, but was achieved on questionnaires in individuals with self-
reported clinical symptoms.13  
De Manincor conducted a single-arm crossover RCT to evaluate the effects of 
individualized yoga therapies on depression and anxiety.10 101 subjects were enrolled 
based on scores obtained from completion of the Depression Anxiety Stress Scale 
(DASS-21). The participants were divided up into either the yoga intervention or the non-
intervention control group. The control group had a 6-week delay in interventions during 
which they maintained regular activities.15 The intervention group participated in six 
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weeks of yoga treatment with certified yoga instructors. A total of four group sessions 
were held. In each session, the instructors worked with each participant to create 
individualized routines that were adapted to the participant’s specific physical and mental 
symptoms.15 Individuals were then encouraged to practice these routines at home in 
between sessions. Compliance with the home regimen was recorded. These 
individualized routines had a mixture of physical postures and movements, breathing 
exercises, relaxation, mindfulness, and meditation techniques.15 At 6 weeks, the control 
group was started on the same individualized yoga training and treatment schedule.10  
On the anxiety subscale of DASS-21, there were no significant reductions of 
anxiety between treatment and control groups (AMD -1.91; 95% CI = -4.58 to 0.76; 
P=.16, effect size = -0.35).15 The researchers determined some data points to be outliers 
due to their Cook’s distance values > 0.04. When these suspected outliers were trimmed, 
the pre- and post-anxiety scores became statistically significant in the treatment group 
(AMD -2.58; CI: -4.71 to -0.35; P=0.02; effect size -0.40).15 Significant reductions in 
scores were also observed in the overall mean composite anxiety, depression, and stress 
scores (AMD -8.77; 95% CI = -16.58 to -0.97; P=.03, effect size = -0.50) between the 
intervention and control groups at 6 weeks post-intervention (P<0.01).15 
The ability to adapt yoga techniques to fit various physical capabilities within the 
home environment and without explicit guidance were some of the benefits observed 
from these individualized, at-home treatments.15 Overall, psychological benefits were 
positive with the yoga interventions, but were not specific to target the anxiety 
symptoms. Despite attempts to minimize selection and performance biases, the study 
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design introduced heterogeneity within the individualized yoga interventions, making it 
difficult to generalize the outcomes to broader groups.  
Boulgarides investigated the potential psychological and physical benefits of yoga 
specifically for patients with PD. Prior to the initial assessment, a medical history, 
Unified PD Rating Scale (UPDRS), and Hospital Anxiety and Depression Scales (HADS) 
were performed. The following physical assessments were also performed: Berg Balance 
Scale (BBS), Modified Dynamic Gait Index (mDGI), 30-second chair stand (TSCS), Sit-
and-Reach tests (SRT), Apley’s Scratch test (AST), Functional Reach Test (FRT), and 
timed Single-Leg Balance (SLB) test.16  
Outcomes from the Boulgarides et al. study were determined through minimal 
detectable changes (MDC), which are the amount of measurable changes in test scores 
that allow the study to confidently state that the change was not the result of 
measurement errors.16 20% of participants achieved MDC for the HADS anxiety 
subscale.16 Post-ANOVA analysis revealed statistically significant mean differences in 
the 30-second chair stand (TSCS) and bilateral sit-and-reach tests (SRT) at  = 0.10.16 
Outcome measures demonstrated significant improvement post-intervention for TCSC ( p 
= 0.03) but a lack of significant changes in the controls (p = 0.39).16 The majority of 
participants (60%) met the MDC of > 1.64 for TSCS with the yoga intervention.16 SRT 
on the right and left side demonstrated significance at p = 0.02 and 0.03 respectively with 
70% of participants achieving an MDC of  >3 inches between fingertips and toes on the 
right and 40% achieving 3.5 inches on the left.16 The study concluded that a sample of 10 
participants was sufficient to observe significant differences in the HADS subscales 
between control and intervention periods at an  = 0.01. For TSCS, a sample size of 33 
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was needed to satisfy an  = 0.01; and for SRT, a sample size of 153 was needed to 
detect significant differences at 80% power and 0.01 level of significance.16  
Despite a small sample size and low statistical power, Boulgarides et al. found 
adequate measures to assess flexibility, strength, motor control, balance, anxiety, and 
depression. The study also showed positive effects of yoga on anxiety and certain 
physical parameters. Boulgarides et al. also minimized confounders by utilizing the same 
cohort for both the control and intervention groups through a waitlist design.  
2.3 REVIEW OF POSSIBLE CONFOUNDING VARIABLES 
Despite the standardization of the mindfulness or yoga group therapies, the 
relationship between participants and instructors occasionally became potential 
confounders. Several studies observed variability among the amount of time instructors 
spent on each individual, either to encourage adherence or to monitor risk.8 However, the 
increased attention from instructors were often found to influence treatment adherence 
and thus primary outcomes.8   
Among group members, participants showed benefits from positive group 
interactions that resulted in greater accountability, increased feedback, and overall social 
support and encouragements.17 The social networking and group interactions could also 
confound results, especially when they were compared to controls or other interventions 
that did not utilize group formats, such as the waitlist controls.8,15 
Aside from group therapies, many studies employed home regimens to be 
practiced between group sessions. De Manincor et al. customized home routines for each 
participant in addition to group yoga lessons. They found that these personalized routines 
confounded effects on anxiety and health status depending on compliance with home 
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practice times and regimen variabilities.15 The heterogeneity of these routines made it 
difficult to determine the efficacy of treatment on the group and also difficult to 
differentiate between the efficacy of one personalized routine over another.15 
As for participant-dependent confounders, compliance to research protocol to 
attend group lessons and to practice home regimens were confounding factors.15 The 
effect of participant adherence as a confounding factor was verified when Kladnitski et 
al. assessed participants’ expectancy of treatment efficacy in each participant at the 
beginning of the study.8 It was determined that adherence was a better predictor of 
outcome than treatment expectancy.8 However, the perceived efficacy of treatment was 
also a reportable factor in determining the participants’ adherence to protocol.8  
Additionally, subjects who have experience with yoga or mindfulness-based 
therapies could also affect the association between interventions and anxiety symptom 
outcomes.18 Hofmann’s study tried to account for this confounding variable by setting an 
ineligibility standard that anyone who had experiences of five or more yoga/mindfulness 
sessions would not be enrolled in the study. 11 Because of this enrollment criteria, 
challenges were reported regarding enrollment of subjects who were treatment naïve to 
both mindfulness and yoga. 
2.4 REVIEW OF RELEVANT METHODOLOGY 
2.4.1 Study Setting and Design 
A literature review was conducted to assess study designs used for yoga and 
mindfulness therapies. There was a clear preference to utilize two-arm randomized 
control efficacy trials with intervention groups receiving standardized yoga or 
mindfulness therapies and control groups receiving a variety of care interventions. These 
interventions ranged from standardized CBT, stress education, and stretch resistant 
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training,11,19 while other control groups took the form of delayed intervention.16,20 The 
interventional groups received weekly, hour-long yoga or mindfulness sessions for 8-12 
weeks in groups of 4-6 participants with 1-2 instructors.11,16,18-20 The addition of home 
independent regimens varied among the studies. Since yoga and mindfulness have the 
greatest impact with consistent practice, the implementation of standardized home 
exercises was ideal for maximizing benefits without confounding the effects of the group 
sessions. Kwok et al. standardized the home workouts to 20-minute practices twice 
weekly with booklets outlining instructions for each exercise.19 Boulgarides et al. 
encouraged home practice but required documentation of time spent on each activity 
(breathing, meditation, and posing exercises).16 Cheung et al. thought home exercises 
would confound results so they refrained from prescribing any independent treatments.20  
Randomization and blinding techniques included randomized computer-generated 
groups blinded to research assistants collecting the data and the statisticians performing 
the data analyses.20 Block permutation stratified by site was utilized in one study to 
ensure equal allocation of participants from each recruitment site to either the control or 
treatment group.11,21 Both methods were able to minimize selection and evaluator biases. 
Other confounders were minimized by matching variables for group formats, frequency, 
duration, venue, and number of participants per group.19 
2.4.2 Selection Criteria 
Participants included in the studies were over 18 years old with moderate PD (as 
determined by Hoehn and Yahr scores of 2-3) and formal DSM-V diagnoses including 
GAD, social anxiety disorder, panic disorder, or agoraphobia.8,11 The H&Y criteria 
excluded participants with either mild PD who were high functioning or those with 
severe PD who had no ability to ambulate unassisted.16  
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Comorbid depressive disorders were allowed in these studies, but other 
psychiatric disorders including PTSD, substance use, eating disorders, organic mental 
disorders, psychosis, bipolar disorders, developmental disorders, or significant suicidal 
ideation were excluded.8,11,22 Pontone et al. justified the inclusion of concurrent 
depressive disorders by their findings where they found no differences in the class or 
dosing of psychiatric medications for anxiety in patients with or without depressive 
comorbidities.4 Therefore, depression was deemed an unlikely confounding factor in the 
treatment of anxiety.3 However, the other psychiatric disorders were likely to affect the 
psychiatric regimen of anxiety or increase the participants’ risk for hospitalization while 
in the study. 
2.4.3 Patient Recruitment and Screening  
Patient recruitment occurred both locally and regionally through convenience 
sampling.19 Most local recruitment came from outpatient neurology and movement 
disorder clinics while broader populations were reached through Parkinson’s disease 
associations, community-based research registries (region dependent), and support 
groups. 10,16,20 Many studies tried to reduce selection biases by widening their search to 
regional databases like PD associations, support groups, and national research registries. 
But there was no evidence to suggest that the socioeconomical or cultural characteristics 
of the local populations were not diverse.10 The results from the local populations were 
therefore deemed generalizable to a larger population. Another issue with recruiting over 
a wide geographic area was the increased travel time for participants and caregivers to 
study sites, which risked attrition and noncompliance to group interventions and follow-
ups. 
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A series of motor and non-motor screening assessments were performed post-
recruitment. Motor assessments included: the Movement Disorder Society - United PD 
Rating Scale (MDS-UPDRS) and an assortment of physical assessments: Berg Balance 
Scale (BBS), Modified Dynamic Gait Index (mDGI), 30-Second Chair Stand (TSCS), 
Sit-and-Reach Test (FRT), and timed Single-Leg Balance (SLB) test.16 Non-motor tests 
included several anxiety and mood assessments: Hospital Anxiety and Depression 
Scale,16 Geriatric Anxiety Inventory,10 Beck Anxiety and Depression inventory20, and 
Hamilton Anxiety Rating Scale11. Having both motor and non-motor assessments as part 
of the screening process ensured that participants could physically execute yoga poses 
and the clinical assessments.  
Hofmann et al. found that despite an overall agreement that anxiety symptoms 
were captured on various anxiety scales, there was no consensus among authors on the 
best cut-off values to determine if symptoms were clinically significant.11 Therefore, 
authors set different threshold levels of anxiety based on their own prior experiences or 
those found in other studies.1 
2.4.4 Data Collection 
Most studies performed evaluator-blinded assessments at baseline (week 0), post-
intervention (week 8 or 12), and at 6 months follow-up.11,16,20 Fewer studies included 
mid-intervention assessments.11  
The assessments at baseline included informed consent, motor, and non-motor 
assessments.16 The same motor and non-motor tests were repeated post-intervention and 
at subsequent follow-ups. Assessing outcomes immediately following the intervention 
period provided data on the short-term efficacy of yoga and mindfulness. The 6 months 
follow-up provided data on the long-term efficacy of these interventions.  
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Most studies intended for participants to maintain consistent practice post-
intervention until the follow-up assessments. However, since there were no organized 
sessions post-intervention, it was difficult to encourage and remind patients to practice at 
home. Dissanayaka et al. incorporated a “telephone mindfulness booster session” to 
refresh knowledge and skills learned from the interventions but also to encourage 
continued practice.10 Based on the above, instead of a telephone session, participants may 
benefit from a 3-months follow-up to ensure continued practice of home regimens. 
Additional data obtained may find correlations between compliance with anxiety and 
motor symptoms. 
2.4.5 Outcome Measures 
For primary outcomes, there were several studies that used either the Beck 
Anxiety Inventory (BAI), Hospital Anxiety and Depression Score (HADS), and Hamilton 
Anxiety Rating Scales (HARS). Leentjens et al. sought to validate the clinimetric 
properties of HARS, BAI, and HADS.22 The study found that all scales (BAI, HADS, and 
HARS) had low positive predictive value and moderate negative predictive value at the 
optimal cut-off scores. This resulted in an underestimation of the severity and prevalence 
of anxiety in PwP.22  
Leentjens et al. then developed a novel scale with improved validity and 
clinimetric properties called the Parkinson Anxiety Scale (PAS).23 The scale was 
intended to be an assessment of anxiety severity rather than a screening or diagnostic 
tool. 23 To create PAS, canonical correlation analysis of questions from HARS, BAI, and 
a Rasch analysis were performed and incorporated to fully capture the spectrum of 
anxiety symptoms. The outcome resulted in a patient- and observer-rated scale comprised 
of 12 items: five items assessing persistent anxiety, four items for episodic anxiety, and 
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three items for avoidance behavior.23 Each item scored on a 5-point Likert scale (0=not or 
never and 4=severe or almost always).23 
Both patient- and observer-rated scales had high AUC (85.1% and 85.9 
respectively), sensitivity, and specificity for any anxiety disorder at the optimal cut-off 
scores, which was set as the threshold for whether a patient had an anxiety disorder or 
not.23 The patient-rated version had better sensitivity (0.81 vs 0.71) but worse specificity 
(0.74 vs 0.91) than observer-rated versions.23  
Face validity was found higher in PAS than existing scales because PAS was able 
to separate clinically evident and relevant domains into separate subscales. PAS was also 
more effective in capturing symptoms of anxiety not otherwise specified (NOS) 
compared to other anxiety scales, since the symptoms of NOS were specific to 
Parkinson’s disease.1,23 The scale eliminated biases towards persistent symptoms that 
were observed in HARS or episodic symptoms, as seen with BAI. Group validity in PAS 
was good, the AUC and Youden index of PAS was higher than in HARS, BAI, or HADS.  
The PAS was validated based on a three-month study period. To date, no 
longitudinal studies have been published regarding the sensitivity of the PAS for anxiety 
symptom changes beyond a year. In addition, anxiety has not been adequately assessed in 
other PD studies. The adjunctive use of the BAI will document the subtleties of episodic 
anxiety. This is more reliable to capture the more mild or transient cases of anxiety given 
an estimated >50% of patients who have some degree of PD related anxiety.11,24 BAI also 
has high internal consistency and test-retest probabilities when assessing the severity of 
anxiety symptoms within the mental health populations.11  
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For secondary outcomes, most studies had a combination of quality of life, health 
status, adherence rates, and motor symptoms.8,13 Health status was an important 
therapeutic outcome in many studies as it often determined the subject’s ability to 
perform physical, emotional, and social activities.4 Many studies found anxiety was 
associated with an additional 17% of variance in health status after controlling for 
depression.4 And anxiety was directly associated with poor health status even after 
factoring out motor disabilities. Many studies utilized either the Parkinson’s Disease 
Questionnaire version-39 or version-8 questionnaires. PDQ-8 is a shortened form of 
PDQ-39, which is the most frequently used questionnaire that explores patient-reported 
measures of health status. Both assess the impact of Parkinson’s disease on functioning 
and well-being across eight different dimensions including relationships, social situations 
and communication.25 If PDQ-8 is used in place of PDQ-39, there is no concern that 
PDQ-8 will be less sensitive or specific as it has summary indices similar to those of 
PDQ-39, with good validity, test-retest reliability, and internal consistency (ICC=0.96).26 
As for motor measurements, Dissanayaka used the Movement Disorder Society 
Unified PD Rating Scale (MDS-UPDRS) to assess motor disability. Both MDS-UPDRS 
and the original UPDRS assess motor function by measuring motor performance, 
activities of daily living, mobility, quality of life, and psychological status.16 The primary 
difference is the addition of more detailed instructions and descriptions of methods for 
data acquisition in MDS-UPDRS, which allows participant to complete the assessment 
without provider input or the need for further clarification.27 MDS-UPDRS was also 
found to better differentiate between the nuances of symptom severity.27  
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The physical assessments in PwP commonly include: the Berg Balance scale, 
modified Gait Index, Functional Reach Test, Sit-and-Reach Test Apley’s Scratch Test, 
the 30-second chair stand, and the single leg balance test. In review of these assessments, 
Boulgarides found that only the single leg balance test (SLB), sit-and-reach test (SRT), 
and the 30-second chair stand (TSCS) demonstrated changes in scores post-yoga 
interventions, and thus recommended only using these outcome measures for future 
studies.16 Although there are few studies using the SLB, SRT, and TSCS that support the 
findings of Boulgarides, for the purposes of this study, these three assessments will 
suffice in assessing participants’ function, balance, and strength.16 
2.4.6 Sample Size and Statistical Analysis 
The meta-analysis performed by Cramer et al. demonstrated that yoga’s effect 
size on depression when compared to aerobic exercises was moderate at 0.59.28 When 
Kwok et al. conducted their study on the effect of yoga on anxiety, their aim was to 
replicate the outcomes. 60-90 participants per arm were calculated to be necessary for 
80% power at a 5% level of significance, with an attrition rate of 20-25%.15,19 
For statistical analyses, Kladnitski et al. compared baseline group characteristics 
and discrepancies among clinical settings using between-subject ANOVAs and chi-
square analyses.8 Both normally-distributed dependent and independent baseline 
variables between the intervention and control groups were analyzed with t-tests.16 For 
variables that were not normally distributed, the Wilcoxon rank sum test and Spearman’s 
rank correlation coefficients were used.16 For within-group comparisons, paired t-tests 
were used and Fisher’s exact test for categorical variables.20 
To identify the differences of mean outcome scores between pre-treatment, post-
treatment, and at follow-up, Analysis of Variance (ANOVA) was used given continuous 
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outcome variables compared in ≥ 3 groups.16 When comparing treatment effects between 
groups, a linear regression was applied after adjusting for the baseline scores and 
levodopa levels.20 For studies with wait-list control groups, a linear mixed model was 
applied, also after adjusting for baseline scores and levodopa levels.11,20 Primary and 
secondary analyses utilized mixed-effects regression models (MRMs) with intention-to-
treat analysis, minimizing any potential attrition.11 
2.5 CONCLUSION 
Both mindfulness and yoga have been shown to be as effective and not inferior to 
current first-line treatments for anxiety disorders29, such as cognitive behavioral therapy 
and pharmacological agents.6 Dissanayaka et al. targeted the use of mindfulness and yoga 
to Parkinson-related primary anxiety disorders and found similar positive outcomes.30 
Although mindfulness and yoga show efficacy and credibility as stand-alone therapies for 
anxiety,8 the long-term effects are not well-established in the PD population. Therefore, 
both are better suited as adjunctive treatments rather than primary mainstay treatments of 
Parkinson-related anxiety.30 The preferred role as adjunctive therapies was further 
examined by Saeed et al. in a systematic literature review, which found a small response 
outcome favoring yoga as a stand-alone therapy. It did not determine any benefit from 
mindfulness as an effective monotherapy for anxiety.5 Interestingly, all of the mentioned 
studies reported no safety risks for either yoga or mindfulness as adjunctive therapies 
when used in conjunction with SSRI, anxiolytics, and CBT.5  
For study designs, yoga and mindfulness demonstrated reductions in symptoms 
when practiced 60-minutes per week for 3-24 weeks.5 Most studies conducted their 
interventions in small group sessions of 4-6 participants and 1-2 instructors. In addition to 
group sessions, the majority of the studies incorporated additional independent at-home 
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exercise routines. The greatest yield was observed when yoga or mindfulness practices 
were standardized to reduce potential confounding effects of the group therapies.19  
Most studies recruited from local neurology offices but often sampled from 
regional sources such as PD associations and support groups. It was noted that when 
recruiting from a large geographic area, there was a higher attrition rate due to the 
inconvenience of increased travel time.  
Participants with moderate Parkinson severity without cognitive impairments or 
comorbid mental health disorders were recruited and referred to these studies. Though 
most mental health disorders like PTSD, eating disorders, or psychosis were excluded, 
comorbid depressive disorders were permissible after Pontone et al. found that it would 
not change the treatments for anxiety disorders.3  
The spectrum of anxiety disorders including persistent or episodic anxiety 
phenomenas31 are now more broadly and accurately captured by the Parkinson Anxiety 
Scale.23 However, its novelty and lack of longitudinal studies warrant supplementation 
with the Beck Anxiety Inventory or the Hospital Anxiety and Depression Scales to better 
capture symptomatic changes over time.32 Secondary outcomes included physical 
abilities, quality of life assessments, medication regimens, and other mood 
symptoms.11,19,20,30 These outcomes have all been studied with positive outcomes in 
studies on yoga and mindfulness therapies. It is likely that this study will not only affirm 
these positive outcomes, but also decipher if one practice may be preferred over another. 
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CHAPTER 3: STUDY METHODOLOGY 
3.1 STUDY DESIGN 
The proposed study will utilize a two-arm, single-blinded randomized controlled 
trial to examine the efficacy of yoga and mindfulness therapies in patients with 
Parkinson-related anxiety. Both treatments will be administered in eight weekly sessions 
by two certified instructors using groups of 4-6 patients. The Parkinson Anxiety Scale 
(PAS) and Beck Anxiety Inventory (BAI) will be assessed at the following time points: 
pre-intervention, post-intervention, 3 months, and 6 months follow-up by research 
assistants blinded to the intervention assignments.  
3.2 STUDY POPULATION 
Patients who received DSM-V based anxiety diagnoses after being diagnosed 
with Parkinson’s disease will be eligible for the study. We will be recruiting patients with 
moderate Parkinson’s disease as determined by a score of 2-3 on the Hoehn & Yahr 
Scale. Patients may be taking pharmacological agents for anxiety, but their dosing must 
remain stable for at least 6 weeks prior to enrollment and throughout the study (barring 
emergency discontinuation). Participants must be fluent in English and have scored >24 
on the Folstein Mini-Mental State Exam (MMSE) to minimize any confounding factors 
associated with cognitive impairments.  
Patients may have comorbid diagnoses of depression but not PTSD, substance 
use, eating disorders, or organic mental disorders. To further minimize confounders, 
patients may not have extensive experiences with yoga or mindfulness therapies (no more 
than 5 lessons taken in their lifetime). More detailed inclusion and exclusion criteria can 
be found in Table 1 below. 
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Table 1. Study Eligibility 
 
Inclusion criteria Exclusion Criteria 
• Ability to give informed consent 
• Age > 18  
• Ability to speak, read, and write 
English 
• New anxiety disorders diagnosed after 
Parkinson’s Disease onset 
• Stable on current medication regimen 
for minimum of 6 weeks with 
intention of continuing during their 
active participation  
• Folstein Mini Mental State Exam 
(MMSE) score >24 
• Scores 2-3 on Hoehn & Yahr scale  
• Parkinson Anxiety Scale score ≥ 12  
• Willingness and ability to perform 
yoga and mindfulness interventions 
and comply with requirements of 
study protocol 
 
• Inability to understand study protocol 
and informed consent process 
• Serious medical illness or potential 
need for hospitalization that will 
interfere with participation in study 
• Significant suicidal ideation or 
behaviors within the past year 
• Cognitive impairments with score 
≤23 on MMSE  
• Comorbidity of dementia, PTSD, 
personality disorder, eating disorder, 
psychosis, or bipolar disorder  
• Prior experiences of more than 5 
yoga or mindfulness sessions 
• Any concomitant psychotherapy  
• Any physical conditions that 
preclude participant from performing 
yoga exercises 
• Frequent alcohol, marijuana/CBD, or 
recreational drug use  
 
3.3 STUDY RECRUITMENT AND SAMPLING  
The proposed study will recruit all its patients from movement disorder, general 
neurology, primary care, and internal medicine clinics within the Yale New Haven 
Hospital system and the greater New Haven area. Patients with idiopathic PD who meet 
eligibility criteria will be invited to participate in the study. 
The screening visit will include the Folstein Mini Mental State Exam (MMSE) 
Hoehn and Yahr Rating Scale (H&Y), Parkinson Anxiety Scale (PAS), and Beck Anxiety 
Inventory (BAI). The H&Y scale will be rated by the principal investigator, Dr. 
Richardson, to determine the severity and progression of the patients’ Parkinson’s 
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disease. Patient will need to have an H&Y score of 2-3 and PAS score ≥ 12 for 
enrollment. This means that the participants will have moderate Parkinson’s disease 
severity and at least mild clinical anxiety symptoms. Formal consent will be obtained 
from the participants who meet these screening criteria to be enrolled into the study.  
3.4 SUBJECT PROTECTION AND CONFIDENTIALITY 
The study will be reviewed by the Human Investigation Committee of Yale 
University School of Medicine and the Yale New Haven Health System. All study 
personnel and staff will be required to complete the Health Insurance Portability and 
Accountability Act (HIPAA) training and the Yale Human Subjects Protection training. 
Any extraction of patient information in electronic medical records will be carried out on 
university or hospital-approved, encrypted, and secured devices. Protected health 
information (PHI) that are non-electronic will be secured in a locked cabinet in the locked 
office of the principal investigator, Dr. Diana Richardson where only she and the co-
investigator will have access. Any PHI will be disposed of in a secure manner after 
completion of study.  
Consent will be provided in written and verbal form by the participant. 
Explanation of consent forms will be provided by trained co-investigator or clinical 
research assistants and participants will be encouraged to voice any questions or concerns 
at the time. The participant will also be allowed to withdraw from the study at any time. 
The consent form will include a detailed study description that will outline the duration of 
participation as well as the potential risks and benefits of the study. English versions will 
be available to the participants, please refer to Appendix A for an example of the 
informed consent.  
3.5 STUDY VARIABLES AND MEASURES 
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3.5.1 Treatment Interventions 
Two active groups will participate in eight weeks of interventions. Each session 
will consist of an hour-long yoga or mindfulness therapy with two certified instructors in 
groups of 4-6. Each yoga and mindfulness session will be matched for group format, 
venue, time, and attention during these sessions. 
The first session will consist of an overview of the intervention and will set group 
and home exercise expectations. For the rest of the mindfulness sessions, participants will 
practice a modified Mindfulness-Based Cognitive Therapy (MBCT) routine for 
Parkinson’s disease. These are listed in Table 2 and will include formal sitting meditation 
exercises, diaphragmatic breathing, and body scanning. 
Yoga sessions will be structured to start with warm-up activities (gentle general 
movements, poses, breathing, and facial/vocal poses and sounds), then transition to 
standing, seated, and lying poses listed in Table 3. Each session will conclude with 
meditation and deep relaxation.  
All participants will be required to practice 20 minutes of their particular 
intervention (yoga or mindfulness) twice a week. The home regimen will be detailed in a 
booklet and will reflect the lessons from that prior week.  
Table 2. Mindfulness Treatment Schedule 
 
Session Key topics 
Week 1 
Introduction to mindfulness 
The mental states of “autopilot” and “mindfulness” 
First-hand experience of mindfulness: the raisin exercise 
Mindfulness practice: body scan 
Week 2 
Relationships between thoughts and emotions 
Awareness of pleasant events 
Mindfulness practice: sitting meditation 
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Week 3 
Mindfulness practice: 3-minute breathing space 
Mindfulness practice: mindful stretching and walking 
Awareness of unpleasant events 
Week 4 
Automatic thoughts (autopilot) can lead to emotional distress 
Practice of meditation techniques learned previously 
Week 5 Sitting meditation focusing on a difficult of stressful situation 
Week 6 
Thoughts are not facts 
Using the 3-minute breathing space in stressful situations 
Week 7 
Relationships between daily activities and depression 
Generate list of pleasure/mastery activities 
Identifying relapse triggers 
Week 8 
Course review 
Keeping a long-term meditation practice going 
 
 Table 3. Yoga Treatment Schedule 
 
Session Key topics 
Week 1 
Introduction to yoga 
Yoga pose practice: Tadasana (basic standing pose), Hasta Chakrasana 
(standing backward bend), and Supta Padangusthasana (knee straight, belt 
over one foot, leg drawn toward head) 
Week 2 
Yoga pose practice: Tadasana Urdhva Baddha Hastasana (Standing 
pose, arms outstretched, fingers intertwined. Palms face forward, then 
arms are lifted so palms face the ceiling), Paschimotanasana (knees apart, 
forward bend putting hands on chair in front) 
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Week 3 
Yoga pose practice: Modified Vrksasana (Balanced on one foot, heel of 
opposite foot placed on ankle of standing foot. Hand on chair if needed), 
Apasana (one knee drawn to chest, then other knee, then both) 
Week 4 
Yoga pose practice: Virabhadrasana 2 (One leg forward, back foot 
slightly turned in. Arms out to sides and head turned in same direction as 
front leg), Marichiyasana (Spinal rotation) 
Week 5 
Yoga pose practice: Modified Trikonasana (one leg forward with toes 
forward. Back foot slightly turned in. Arms out at shoulder level), Spinal 
rolls (knees bent and foot on floor, knees allowed to fall one direction, 
head turned in opposite side) 
Week 6 
Yoga pose practice: Virabhadrasana 3 (One leg forward with knee 
slightly bent. Palms together at chest or raised slightly overhead), Jathara 
parivartasana (one leg straight, opposite knee drawn out to the side) 
Week 7 
Yoga pose practice: Ardha Chadrasana (Legs together, arms overhead, 
thumbs intertwined. Stretch done on one side then the other), Setu 
Bandhasana (Bridge, with arms at sides, hips lifted off floor 
Week 8 
Course review 
Keeping a long-term yoga practice going 
 
3.5.2 Primary Outcome Measures  
The primary outcome measures will demonstrate improvements and remissions of 
anxiety symptoms according to the Parkinson Anxiety Scales (PAS) and Beck Anxiety 
Inventories (BAI). For PAS, both a patient-rated and an observer-rated scale will be 
completed to accurately assess the severity of anxiety symptoms. Both scales will be 
comprised of 12 items: five items assessing for persistent anxiety, four items for episodic 
anxiety, and three items for avoidance behavior.1 Each item will then be scored on a 5-
point Likert scale (0=not or never and 4=severe or almost always).1  
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To further capture the full spectrum and progression of a patient’s anxiety 
symptoms, self-reported BAI will supplement the PAS. BAI is a 21-item self-reported 
inventory that assesses episodic symptoms that have bothered participants in the recent 
month, for example, inability to relax, dizziness, or racing heart. Decreases in PAS and 
BAI scores over time will signify clinical improvements in anxiety symptoms. For the 
schedule of assessments, refer to Table 4.  
3.5.3 Secondary Outcome Measures 
Secondary outcomes will include any changes in health status scores (PDQ-8) and 
motor symptoms as measured by MDS-UPDRS and physical tests. Additionally, any 
changes in the patient’s medications for anxiety will be assessed by the PI, Dr. 
Richardson at baseline, post-treatment, and subsequent follow-ups. 
PDQ-8 will be used to determine any reductions in self-reported health status 
outcomes, an important therapeutic outcome in the treatment of Parkinson’s disease. Low 
PDQ-8 scores demonstrate strong abilities to perform physical, emotional, and social 
activities.2  
The patient’s motor symptoms will be evaluated by Dr. Richardson on the 
Movement Disorder Society – Unified PD Rating Scale (MDS-UPDRS). MDS-UPDRS 
is a clinimetric assessment that rates 65 items that include the non-motor experiences of 
daily living, motor experiences of daily living, motor examination, and motor 
complications. There will be 20 questions completed by the patient and a fourth section 
that will be completed by the medical provider to assess motor fluctuation and 
dyskinesias. The minimum detectable change (MDC), which is the amount of change in 
test scores needed to ascertain a true measurable change, has not been studied in MDS-
UPDRS but is 13 points in the original UPDRS. 
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The physical tests will include the 30-second chair stand, single-leg balance test, 
and sit-and-reach tests. The 30-second chair stand demonstrates function, balance, and 
leg strength by counting the number of times the patient can alternate between sitting and 
standing without the use of their arms in 30 seconds. The minimum detectable change 
(MDC) for this study will be 1.64 repetitions.3  The single-leg balance test measures the 
duration a patient can stand on one leg, which is a proxy test for fall risks in older adults.3 
Lastly, the sit-and-reach test measures the distance from fingertips to toes when the 
patient reaches their hands toward an extended leg while seated on the edge of the chair. 
The other side is then repeated in the same way. There is no recorded MDC in PwP but 
the MDC is 3 inches on the right and 3.5 on the left in patients with type 2 diabetes.3 
3.6 METHODOLOGY 
The PAS, BAI, PDQ-8, MDS-UPDRS, and physical assessments will be 
administered prior to randomization of participants. In an effort to minimize selection 
bias, the study will utilize non-clinical personnel or a third-party statistician to randomize 
groups using a computerized random number generator. Participants will either be placed 
into (1) yoga and treatment-as-usual group or (2) mindfulness and treatment-as-usual 
group. To further minimize selection bias, each participant will be de-identified and 
assigned an arbitrary study-related number. The treatment assignments will also be 
concealed from the clinical research assistant and medical provider who will be 
administering the PAS, BAI, PDQ-8, MDS-UPDRS, and physical exam assessments.4 
The two treatment groups will be matched closely on group formats, frequency (8 
weeks), duration (60 minutes), number of participants per group (4-6), and venue. Each 
of the mindfulness and yoga group sessions will undergo monitoring to ensure adherence 
to treatment protocols. Each session will be audio-recorded and 20% of each recording 
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will be graded to ensure that the participants receive appropriate forms of treatment, 
comparable instructions, and similar amount of attention from instructors. The 
mindfulness and yoga instructors will collect the home regimen diary, documenting 
adherence to the assigned therapy (20 minutes of daily practice, twice a week). These 
records will then be given to the research assistants.  
The MBCT and yoga therapies have all been adapted to fit the physical 
capabilities of PwP, and previous studies have reported no specific safety concerns. 
However, adverse events will be monitored directly by the two instructors during the 
group sessions as participants will be exposed to new techniques of mindfulness or yoga 
during that time.  
3.7 DATA COLLECTION 
The timing of each assessment is listed in Table 4. Once consent has been 
received from each participant, they will undergo assessment and interviews with the 
clinical research assistant (CRA) to gather baseline demographics (age, sex, years of 
education, family history of Parkinson’s or psychiatric disorders). Therapeutic and 
histories will be obtained to determine anxiolytic regimen and for other medical histories 
that may affect study.  
At baseline, both the evaluator- and self-rated Parkinson Anxiety Scale (PAS) and 
Beck Anxiety Inventory (BAI) will be administered, which will continue post-
intervention, at the 3 months, and 6 months follow-up. For secondary measures, the PI, 
Dr. Richardson, will assess for any changes in physical abilities using MDS-UPDRS and 
other required physical assessments (30-second chair stand, single-leg balance test, and 
sit-and-reach tests). The PDQ-8 will also be administered, and the clinical research 
assistant will interview the patient to elucidate pharmacologic adherence and any changes 
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in anxiolytic regimen. Follow-up appointments will be in-person and scheduled at the 
post-intervention visit with email and phone reminders sent out the day before to prevent 
attrition.  
Table 4. Timeline of Assessments  
 
 
Note: f/u = follow-up 
 
3.8 SAMPLE SIZE CALCULATION 
For a clinically significant effect size of 0.6 to be detected, a 2.1 and 3.4 points 
difference on PAS and BAI respectively would need to be measured between baseline 
and post-intervention. The study will utilize Cohen’s categories in determining 
magnitude of overall effect with a small differential ranging from SMD = 0.2-0.5; 
medium from SMD = 0.5-0.8, and large SMD>0.8.5 This study will aim for a moderate 
effect size of SMD ≈ 0.6 given the time and resource constraints of the study while 
maintaining a power of 80% and an alpha of 0.05. The sample size will include 69 
participants per group, assuming from previous studies that a maximum of 20% of 
participants may withdraw.  




















Screening X X X X X X    
Baseline      X X X X 
Post-Tx      X X X X 
3 mo f/u      X X X X 
6 mo f/u      X X X X 
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The intention-to-treat principle will be applied to all statistical tests to reduce 
attrition. Demographic and Parkinson diagnostics features between both groups will be 
analyzed using Welch’s t-test or chi-square tests. For within-group comparisons, paired t-
tests will be used and Fisher’s exact test for categorical variables.  
Short-term, medium-term, and long-term outcomes will be analyzed separately 
with short-term outcomes defined as post-intervention (week 8), medium-term as 3 
months follow-up, and long-term as 6 months follow-up.  
Standardized mean differences (SMD) with 95% confidence intervals will be 
calculated from mean differences divided by pooled standard deviation for primary and 
secondary outcomes.5 Negative SMD will indicate beneficial effects of yoga or 
mindfulness at post-intervention or follow-ups compared to baseline. Repeated measures 
of Analysis of Variance (ANOVA) will be used when assessing for change in more than 
two time points, such as when assessing for the changes in anxiety scores, PDQ-8, and 
MDS-UPDRS. For all procedures, the statistical tests will be 2-tailed with an alpha set at 
0.05. 
Table 5. Demographics and Analysis  
 
 
Yoga and TAU 
(N = 69) 
Mindfulness and 
TAU (N = 69) 
Test for Significance 
Demographic Features    
Age (y), mean (SD)   Paired t-test 
Sex (male/female)   2 
Years of education, mean 
(SD) 
  Paired t-test 
MMSE, mean (SD)   Paired t-test 
Health Status (PDQ-8), 
mean (SD) 
  Paired t-test 
Family history of PD, % 
(N) 
  2 
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Family psychiatric 
history, % (N) 
  2 
PD Features    
Age symptom onset (y), 
mean (SD) 
  Paired t-test 
Symptom duration mean, 
(SD) 
  Paired t-test 
Hoehn & Yahr stage   2 
Presence of unpredictable 
off periods, % (N) 
  2 
Total levodopa 
equivalents, mean (SD) 
  Paired t-test 
Psychiatric Features and 
Comorbidities 
   
Presence of comorbid 
depressive disorder, % 
(N) 
  2 
Presence of multiple 
anxiety disorders, % (N) 
  2 
Current Anxiolytic 
regimen (% Daily/PRN) 
  2 
Compliance of Study 
Interventions 
   
Mean sessions attended 
(Total = #) 
  Paired t-test 
Mean home practice 
minutes/week (range) 
  Paired t-test 
 
3.10 TIMELINE AND RESOURCES 
Once the study application is submitted and IRB approval is obtained, recruitment 
in movement disorder, general neurology, and primary care clinics within the Yale New 
Haven Hospital System and greater New Haven area will commence. Site recruitment 
and participants referrals will be ongoing for 12 months or until the enrollment goal has 
been achieved.  
During the recruitment period, those who meet eligibility criteria will be invited 
to the study. Once screening and enrollment are completed, the participants will be 
randomized to an intervention group where they will complete an eight-week course of 
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either yoga or mindfulness interventions with 6 months of follow-up. The entire study 
will be expected to finish under two years. 
A binder will include all consent forms and the number/letter assignments of the 
participants. There will be separate participant folders for all the surveys and 
questionnaires. All binders and folders will be placed in a locked cabinet in Dr. 
Richardson’s office where only the investigators and clinical research assistants will have 
access. 
Study personnel will include: 
▪ Principal investigator and co-investigator: Dr. Diana Richardson and Winifred 
Tung, PA-SII 
▪ Clinical research assistants (1 per 12 patients)  
▪ 2 yoga instructors and 2 mindfulness instructors 
▪ Third-party statistician/data analyst 
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CHAPTER 4: CONCLUSION 
4.1 ADVANTAGES AND DISADVANTAGES 
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In the recent decade, validation studies have been conducted on the safety of yoga 
and mindfulness for patients with Parkinson’s disease (PwP). However, none of these 
studies assessed their effects on anxiety specifically in this population. There are a 
limited number of clinical measures available to track the severity of anxiety associated 
with Parkinson’s disease. The scales that are available are often too specific and do not 
capture the full spectrum of anxiety disorders. This study addresses gaps in both the 
measurement and management of Parkinson-related anxiety by 1) using adaptive yoga 
and mindfulness regimens to reduce anxiety symptoms in patients with moderate PD, and 
2) by using an assessment appropriate for measuring anxiety in Parkinson’s disease.  
The Parkinson Anxiety Scale (PAS) has high sensitivities and specificities for a 
wide range of DSM-V based anxiety disorders. Although the PAS has been validated in 
this study population for the assessment of anxiety disorders, it requires supplementation 
with additional rating scales due to the need for a more longitudinal assessment tool.1 
Researchers have suggested the use of BAI to supplement PAS when assessing 
longitudinal changes of anxiety in this population. Although there is a 6-month follow-up 
in this study, it is insufficient to determine any long-term benefits of yoga or mindfulness. 
Future studies may benefit from including a longer monitoring period.  
  There may have been confounding effects of sample bias if participants enrolled 
into the study with preconceived expectations of the benefits of yoga or mindfulness 
therapies. In this case, they may have been more motivated to practice at home or 
minimize their anxiety when completing questionnaires.2 One way to combat the placebo 
effect in future studies is to screen participants for preconceptions or assumptions they 
may have for the efficacy of yoga. Another potential confounder is that the group 
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sessions share features of a support group atmosphere, fostering placebo effects. This 
effect may not occur at the follow-up visits, where the participants are solely completing 
home individualized exercises. These potential confounders will all need to be further 
explored in future studies with longer periods of follow-up.  
As yoga and mindfulness practices become more mainstream in the community, 
there is greater feasibility of using these interventions as therapies. There likely will be 
few barriers to hiring certified instructors to lead modified mindfulness and yoga 
treatment sessions. Additional studies would be appropriate to determine efficacy across 
the spectrum of the PD population. The mindfulness and yoga programs used in the study 
were scripted, so we cannot assume that other programs in the community would be 
tailored to the PD population. Instead, comparisons of various modified yoga or 
mindfulness programs will be useful to determine the most suitable regimen for PD-
related anxiety disorders. 
4.2 CLINICAL AND/OR PUBLIC HEALTH SIGNIFICANCE 
The advantages of yoga and mindfulness as adjunctive therapies are two-fold: 
addressing anxiety at a low-cost and minimizing polypharmacy. Since Parkinson’s 
disease (PD) is a chronic neurological condition, rehabilitation is usually limited to 
periods of exacerbation or functional decline due to cost.2 Unlike the accepted referrals to 
rehabilitation for motor deficits, symptoms of anxiety are often inadequately addressed 
by clinicians. Since yoga and mindfulness regimens can be adapted and practiced at home 
for management of anxiety, the cost of therapy is minimal in comparison to potential 
hospitalizations or medications. The benefits of the yoga or mindfulness regimens will 
also have cumulative and lasting positive effects.  
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Polypharmacy in patients with Parkinson’s disease (PwP) is common where four 
or five classes of dopaminergic medications may be prescribed. This is then often 
combined with anxiolytics and other medications for non-neurological conditions. Many 
of these medications may have side effects such as nausea, vomiting, and drowsiness. 
The advantages of modified yoga and mindfulness are avoidance of pharmacological side 
effects in addition to minimal safety risk for falls or injury. 
The prevalence rates of anxiety among PwP vary widely (6-55%) and lifetime 
prevalence rates far exceeds that of the general population.3 Since anxiety significantly 
affects quality of life, sleep, concentration, and energy levels2, patients suffering from 
PD-related anxiety need therapies that will directly address the psychological and 
physical consequences of their symptoms. Both yoga and mindfulness have been found to 
improve health status while decreasing stress and clinical symptoms of anxiety. 
Additional studies are warranted to fully explore the benefits of these therapies in 
Parkinson’s disease and similar neurodegenerative illnesses. 
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Appendix A: Consent and Privacy Rule Authorization Form 
 
CONSENT FOR PARTICIPATION IN A RESEARCH STUDY 
Adapted from 200 PR.1 Informed Consent for Research Participation: Competent Adult 
Participants  
 
Title of Study: The Effects of Yoga Versus Mindfulness on Anxiety in Individuals with 
Parkinson’s Disease 
Principal Investigator: Diana Richardson, M.D. 
Co-Investigator: Winifred Tung, PA-SII 
Affiliation: Yale New Haven Hospital and Yale School of Medicine  
 
Invitation to Participate and Study Purpose: 
  
We would like to extend an invitation to participate in our study of yoga and mindfulness 
therapies for Parkinson-related anxiety. You have been referred because you have been 
previously diagnosed with Parkinson’s disease as well as with an anxiety disorder. The 
current study will enroll 120 total participants from primary care, internal medicine, 
general neurology, and neurology movement disorder clinics in the YNHH system and 
within the greater New Haven area. Active participation in the study will require a total 
of 10 months from enrollment and baseline assessments to the last follow-up.  
 
To decide your willingness to participate, please continue to read the following details 
about the study. A research staff member will then review the purpose, procedures, risks, 
and benefits of the study and to make sure that all questions or concerns are addressed.  
 
Description of Study and Procedures: 
 
▪ Enrollment in this study requires that you meet set inclusion and exclusion 
criteria. These criteria are as follows:  
 
Inclusion criteria Exclusion Criteria 
• Ability to give informed consent 
• Age > 18  
• Ability to speak, read, and write 
English 
• New anxiety disorders diagnosed after 
Parkinson’s Disease onset 
• Stable on current medication for 
minimum of 6 weeks with intention of 
continuing stable dose  
• Folstein Mini Mental State Exam 
(MMSE) score >24 
• Inability to understand study protocol 
and informed consent process 
• Serious medical illness or potential 
need for hospitalization that will 
interfere with participation in study 
• Significant suicidal ideation or 
behaviors within the past year 
• Cognitive impairments with score 
≤23 on MMSE  
• Comorbidity of dementia, PTSD, 
personality disorder, eating disorder, 
psychosis, or bipolar disorder  
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• Willingness and ability to perform 
yoga and mindfulness interventions 
and comply with requirements of 
study protocol 
• Assessment on Hoehn & Yahr scale is 
stage 2-3 
• Parkinson Anxiety Scale score ≥ 12 
for enrollment 
 
• Prior experiences of more than 5 
yoga or mindfulness sessions 
• Any concomitant psychotherapy  
• Any physical conditions that 
preclude participant from performing 
yoga exercises 
• Frequent alcohol, marijuana/CBD, or 
recreational drug use  
 
▪ A written informed consent form (this document) is to be signed by both you, the 
participant, and the Primary Investigator (Dr. Diana Richardson) or Co-
Investigator (Winifred Tung, PA-SII). The purpose of this informed consent is to 
outline the study purpose and study designs so that you will understand your 
responsibilities as a participant in the study. Enrollment in this study is optional. 
Once enrolled, you may discontinue your enrollments at any time with 
notification to the PI. 
▪ Following enrollment in the study, additional demographic and pertinent medical 
history will be obtained regarding your diagnosis of Parkinson’s disease and of 
your diagnosis of anxiety. We will also require a detailed list of your current 
medications and may request additional information of relevant family medical 
history. If needed, we may request that you provide medical records from doctors 
who manage your Parkinson’s Disease and your anxiety. This study is HIPAA 
compliant so that no personal identification information will be associated with 
the study documents completed as a result of your participation. 
▪ During your participation in this study, you will complete various written and 
physical evaluations. These assessments will be performed on five different visits 
throughout the 10-month period. The written assessments will be questionnaires 
regarding your anxiety symptoms, thinking ability, and physical abilities. There 
will also be three physical tests to determine strength, ability to maintain balance, 
and fall risks.  





















Screening X X X X X X    
Baseline      X X X X 
Post-Tx      X X X X 
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▪ You will be assigned to one of two treatment groups by a random process such 
that each group will have an equal number of participants with similar degrees of 
Parkinson’s and anxiety. One treatment group will receive yoga therapy and the 
other group will receive the mindfulness therapy. Each group will meet once a 
week for 60 minutes for 8 consecutive weeks. Each group will have 3-5 other 
participants, including yourself, and 1-2 instructors. Details of these therapies will 
be explained in full prior to and at the treatment sessions. You will be required to 
attend each treatment session, and the need to make-up sessions will be evaluated 
on a case-by-case basis.  
▪ In the case that you miss more than 2 treatment sessions or rating sessions, you 
will be automatically un-enrolled from the study. 
▪ In addition to group sessions, there will be detailed yoga or mindfulness home 
exercises to complete. You will be required to complete these twice per week and 
record the times in a diary. The exercises will reflect what is learned in the 
preceding group sessions that week. 
 
Risks or Inconveniences: 
 
This study is deemed low to no risk. There are no specific physical risks associated with 
participation in this study. Due to the nature of Parkinson’s disease, baseline physical 
symptoms may increase risks for falls. The yoga and mindfulness interventions have been 
adapted for Parkinson’s disease and tested in previous studies with no adverse 
consequences. As for anxiety symptoms, yoga and mindfulness are not expected to 




The mindfulness or yoga therapies may improve anxiety symptoms and reduce the need 





There will be no costs for participation in the study; however, there will also be no paid 
reward for enrollment in the study. 
 
Confidentiality of Information: 
 
Any identified information obtained or reviewed in this study will remain confidential 
and only disclosed as require by the United States or Connecticut law. Only the parties 
listed in the research authorization form attached will be granted access to identifiable 
information we collect. When the study is published, there will be no information that 
3 mo f/u      X X X X 
6 mo f/u      X X X X 
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will link your identity to the study unless you give specific permission to disclose 
personal information.  
 
If needed, your information in electronic medical records will only be accessed through 
university approved, encrypted, and secure electronic devices. All healthcare providers 
will be subject to the Health Insurance Portability and Accountability act (HIPAA). Any 
data on paper will be kept in binders in a locked cabinet in the locked office of the 
principal investigator.  
 
Research Subject’s Rights 
 
You are able to decline enrollment into the study and may discontinue participation at 
any point throughout the study. However, any data gathered prior to withdrawing 
participation may still be used in the study analyses to ensure study integrity and study 
oversight. There will be no penalty or loss of benefits associated with withdrawal of 
participation. Please notify the Primary Investigator, Dr. Diana Richardson or Co-




I have read (or have ben read) this form and have decided to participate in the project 
described. The general purpose, risks, and benefits are clear and acceptable to me.  
 
By signing this form, I give permission to researchers to use information about myself 
and my child for the purposes described in this form. By declining participation, I 
understand that I will not receive the therapies in this study.  
 
Name of Participant (Print): ___________________ 
 
Signature of Participant: __________________  Date: ______________ 
 
Name of Person Obtaining Consent (Print): ______________________ 
 
Signature of Person Obtaining Consent: ________________Date: ______________ 
 
Any further questions or concerns about this research project may be directed to the 
Principal Investigator at her office: Dr. Diana Richardson 203-932-5711 x 4724 
 
If after you have signed this form you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919.  
 
If you have questions about your rights as a research participant, or you have complaints 
about this research, you can contact the Yale Institutional Review Boards at 203-785-














Investigator:   




Information:   
 
   
 
To the Subject: 
 
The health-related information that we gather about you in this study is personal.  The Yale School 
of Medicine and the Yale New Haven Hospital researchers are required by law to protect the 
privacy of the information known as protected health information or PHI.  All reasonable efforts 
will be made to protect the confidentiality of your PHI, which may be shared with others to support 
this research, to conduct public health reporting, and to comply with the law as required.  Despite 
these protections, there is a possibility that information about you could be used or disclosed in a 
way that it will no longer be protected by federal law.  For example, some of the individuals listed 
on page 2 of this form may not be required by law to meet HIPAA standards for privacy of health 
information.  These individuals or companies are nonetheless required through other agreements 
with Yale to keep your information confidential. 
 
In this form, we describe who will be working with this information and ask for your permission 
to use the information in the research study. 
 
Please read this form carefully.  If you have any questions, please ask the Principal Investigator 
listed above before signing this form. 
 
By signing this form, you give permission for the researchers to use and/or disclosure the 
information as described below, for this research study.  The reason for the uses and disclosures is 
to assess yoga and mindfulness effects on anxiety symptoms related to Parkinson’s disease.  
 
You have a right to refuse to sign this form.  Your health care outside the study, the payment for 
your health care, and your health care benefits will not be affected if you do not sign this form. 
 
If you do not sign this form, you will not be able to enter this research study and will not receive 
treatment as a study participant. 
 
If you sign this form, you may change your mind at any time, but the researchers may still use the 
information collected before you changed your mind in order to complete the research.   
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This form will never expire unless and until you change your mind and retract it.  To retract the 
permission to use your information, please tell the study staff or write to Dr. Diana Richardson or 
Winifred Tung, PA-SII.  
 
You will not be allowed to see or copy the part of your medical records that describe a research 
treatment until the research is completed, but you may see and copy the research treatment 
information at the end of the research in agreement with institutional medical record policies. 
 
You have a right to receive a copy of this form after you have signed it.  If after you have signed 
this form you have any questions about your rights, please contact the Yale Privacy Officer at 
203/436-3650. 
 
Use and Disclosure Covered by this Authorization 
 
(1) Who will disclose, receive, and/or use the information?   
The following person(s), class(es) of persons, and/or organization(s) may share, use, and receive 
the  
information listed below in connection with this Study.  These persons are authorized to use and 
disclose the information to the other parties on this list, to you or your personal representative, or 
as permitted by law. 
 
❑ The following health care facilities or research site(s) and research staff involved in this study: 
YNHH, Yale School of Medicine, Research Investigators, Clinical Research Assistants 
❑ Health care providers at your PCP, neurology, or movement disorder clinic who referred and 
connected you to this study 
❑ Laboratories and other individuals and organizations that analyze your health information in 
connection with this study, in accordance with the study’s protocol 
 
❑ The members and staff of the Human Investigation Committee that approved this study 
❑ Those individuals at Yale who are responsible for the financial oversight of research 
including billings and payments 
 
❑ Principal Investigator: Dr. Diana Richardson  
❑      Additional members of the Research Team  
 
❑ Data and Safety Monitoring Boards and others authorized to monitor the conduct of the Study 
❑ Others (as described below)  
 
(2) What personal health information will be used or disclosed?    
The following information about you may be used and disclosed: 
❑ Research study records. 
❑ Medical and laboratory records of only those services provided in connection with this Study.   
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❑ The entire research record and any medical records held by Yale New Haven Hospital created 
from: _Parkinson’s disease diagnosis________ to: ___present_____ 
  
❑ The following information: 
Signature 
I have read this form and all of my questions about this form have been answered.  By signing below, I 
authorize the described uses and disclosures of information. 
 
_________________________________________ 
Signature of Subject or Personal Representative 
 
_________________________________________ 






Description of Personal Representative’s Authority 
 
 
THE SUBJECT OR HIS OR HER PERSONAL REPRESENTATIVE MUST BE PROVIDED 
WITH A COPY OF THIS FORM AFTER IT HAS BEEN SIGNED 
 
 









Appendix B:  Hoehn & Yahr Rating Scale*  
• Stage 0 indicates no sign of disease 
• Stage 1 indicates unilateral disease 
• Stage 2 indicates bilateral disease without impairment of balance 
• Stage 3 indicates mild to moderate bilateral disease with some postural instability, 
but physically independent 
• Stage 4 indicates severe disability, but able to walk or stand unassisted 
• Stage 5 indicates confinement to bed or wheelchair unless aided by someone else 
 
* Interpretation of rating scale results: Hoehn & Yahr Stage 0 & 1 (mild), Hoehn & Yahr 








*Used to assess cognitive and mental faculties; scores 24-30 indicates normal cognition. 
 
 






















PDQ-8 will assess health status across eight different dimensions including relationships, 
social situations and communication. 
 



















































































Adapted from Kabat-Zinn’s Mindfulness Based Stress Reduction 
 
 
Appendix J: Participant Diary of Home Regimen 
 
Subject #   
 Date Amount of Time 
Week 1   
Week 1   
Week 2   
Week 2   
   
   
   









Sample size calculations were performed with Glimmpse. Power calculations indicated a 
sample size of at least 55 participants were needed to detect a 1 SD difference between 
groups in the primary outcome anxiety measures. This means 2.1 and 3.4 points 
differences on PAS and BAI respectively. An attrition rate of 20% was accounted for, 
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